Eyevance Enters into Exclusive Licensing Agreement for ZERVIATE™


Share on facebook
Share on twitter
Share on linkedin

Eyevance Pharmaceuticals LLC™, a Recently Established Ophthalmic Company, Enters into an Exclusive Licensing Agreement for ZERVIATE™ in the United States, the First Topical, Ocular Formulation of the Antihistamine Cetirizine


  • Eyevance Pharmaceuticals is a private equity-backed, specialty pharmaceutical start-up, founded by successful ophthalmic executives
  • Mission to market a portfolio of products that address significant unmet needs, including rare and orphan conditions, while also focusing on products with a legacy of proven safety and efficacy

Fort Worth, Texas – September 22, 2017: Eyevance Pharmaceuticals, LLC (“Eyevance”), a specialty pharmaceutical company with the singular focus to build a profitable, sustainable, and growing specialty ophthalmic platform, has entered into an exclusive licensing agreement with Nicox Ophthalmics Inc., a subsidiary of Nicox S.A. (“Nicox”; Euronext Paris: COX). Under the terms of the agreement, Eyevance received commercialization rights to ZERVIATE™ (cetirizine ophthalmic solution) 0.24% in the U.S. ZERVIATE™ is the first topical formulation of the antihistamine cetirizine approved for the treatment of ocular itching associated with allergic conjunctivitis. Cetirizine, the active ingredient in the systemic drug Zyrtec®1, is a second-generation antihistamine which has a well-characterized systemic efficacy and safety profile with world-wide exposure resulting from 20 years of oral use.2

In accordance with the exclusive license, Nicox received a payment upon closing and is eligible to receive future contingent milestones and tiered royalty payments on net sales.

Eyevance’s management team and advisors’ track record of acquiring, developing, and commercializing innovative and impactful specialty pharmaceutical products spans over 80 years. Eyevance, co-founded in September 2017, is led by ophthalmic veterans Jerry St. Peter, Chief Executive Officer and Jason Werner, Chief Operating Officer. Most recently, Mr. St. Peter and Mr. Werner spearheaded the inaugural buildout and launch of the ophthalmic business at Sun Pharmaceutical Industries, Inc. (“Sun” or “Sun Pharma”). While operating at Sun, Mr. St. Peter led the overall ophthalmic business unit and pioneered its U.S. entry, while Mr. Werner was responsible for commercial development and strategy, leading the acquisitions of InSite Vision and Ocular Technologies, Sarl. Prior to building the ophthalmic commercial organization at Sun Pharma, Mr. St. Peter and Mr. Werner held executive positions at Foresight Biotherapeutics Inc. (acquired by Shire plc in 2015), Nicox Inc. (acquired by Valeant Pharmaceuticals International, Inc. in 2014) and Inspire Pharmaceuticals Inc. (acquired by Merck & Co. in 2011).

“The Eyevance team is excited and proud to partner with Nicox to provide patient access to ZERVIATE™ in the U.S.,” commented Jerry St. Peter, Co-Founder and Chief Executive Officer, Eyevance Pharmaceuticals. “As a new entrant to the ophthalmic space, our mission is clear and focused: To develop and commercialize innovative, impactful eye care products that improve vision, restore health, and elevate patient quality-of-life. The opportunity to commercialize ZERVIATE™, a clinically-proven and time-tested molecule, for patients suffering from allergic conjunctivitis represents the first momentous step towards achieving our mission.”

Jason Werner, Chief Operating Officer, Eyevance Pharmaceuticals added: “Our long-term portfolio strategy is focused on the acquisition of products and product candidates that address a significant unmet need and have been demonstrated as safe and efficacious in the clinic. We seek to strengthen our pipeline with synergistic assets while delivering unparalleled service to ophthalmologists and optometrists nation-wide.”

Important Information about ZERVIATE™

INDICATION: ZERVIATE™ (cetirizine ophthalmic solution) 0.24% is indicated for treatment of ocular itching associated with allergic conjunctivitis.

DOSAGE AND ADMINISTRATION: The recommended dose is one drop in each affected eye twice daily (approximately 8 hours apart).

The most commonly reported adverse reactions occurred in approximately 1-7% of patients treated with either ZERVIATE or vehicle. These reactions were ocular hyperemia, instillation site pain, and reduction in visual acuity.

About Eyevance Pharmaceuticals LLC

Eyevance Pharmaceuticals is a U.S. based company committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision and better quality of life for all patients. Eyevance seeks to establish a portfolio of products that address significant unmet needs, including rare and orphan conditions, while also focusing on products with a legacy of proven safety and efficacy. The company’s strategy will leverage the deep knowledge of its management team within ophthalmology and optometry.

About Nicox S.A.

Nicox S.A. is an international ophthalmic company developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has one product at the review stage with the U.S. Food and Drug Administration (FDA), VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, licensed worldwide to Bausch + Lomb, and one product with an approved NDA, ZERVIATE (cetirizine ophthalmic solution) 0.24%, licensed in the U.S. to Eyevance. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

1. Zyrtec® is a trademark of UCB Pharma SA or GlaxoSmithKline.
2. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020346, accessed, 10Aug17.

For More Information, Please Contact:
Jason Werner
Chief Operating Officer, Eyevance Pharmaceuticals LLC